HKUST DRAP Students Participated in the 10th CBIIC Conference in Nanjing
The 10th China BioMed Innovation and Investment Conference (CBIIC) was successfully held in Nanjing, bringing together leading experts, policymakers, investors, and industry representatives to explore the latest developments and future directions of the biomedical and pharmaceutical sectors in China and beyond. The conference serves as a key platform for advancing innovation, collaboration, and investment in the life sciences industry.
This year, Our DRAP Program was honored to be invited by the HKBMIA to participate in this landmark event.
During the conference, Professor Karl Tsim, Director of the DRAP program, was invited as a panelist to share his insights on “How Hong Kong Can Serve as a Strategic Anchor for Chinese Pharmaceutical Innovation.” His participation highlighted Hong Kong’s unique position as a bridge for scientific research, international collaboration, and regulatory convergence between Mainland China and the global market.
Following the conference sessions, DRAP students were invited to an exclusive networking dinner, where they had the valuable opportunity to connect with representatives from the China Pharmaceutical Innovation and Research Development Association (PhIRDA), former FDA reviewers, and various industry leaders. These interactions offered students firsthand exposure to current trends, challenges, and opportunities within the rapidly evolving pharmaceutical innovation landscape.
The DRAP program’s participation in the 10th CBIIC not only deepened students’ understanding of the biopharmaceutical ecosystem in China but also strengthened HKUST’s ties with key stakeholders in the region—further reinforcing the program’s mission to cultivate future leaders in drug regulatory affairs and pharmaceutical policy.